Abbott Laboratories (NYSE:ABT) soared 0.80% during previous trade, a total of 6.40M shares exchanged hands compared with its average trading volume of 9.07M shares whereas its relative volume is 0.70. The stock has a market capitalization of $78.16B along with 1.73B outstanding shares. Stock’s intraday price range hit the peak level of $45.46 and touched the lowest level of $44.92.
Most recently Abbott Laboratories (NYSE:ABT)’s price target was revised on 03/02/17 and according to 13 analysts stock’s price will reach at $47.77 during 52 weeks with standard deviation of 2.83. Stock’s minimum price target estimates has been figured out at $41 while the maximum price target forecast is established at $51, if we look at the price target with an optimistic approach it has upside potential of 12% from its latest closing price of $45.36.
Historically, if we look at price target revisions, two weeks ago Abbott Laboratories (NYSE:ABT)’s price target was revised on 2/17/17 by the analysts, however the bullish price estimates of the stock set at $51 while the bearish estimates kept at $42 over the next one year. Stock’s 52-week target was retained at $47.56, the estimates indicates a standard deviation of 2.79.
While taking an overview of recommendation trends, the stock currently has an average brokerage recommendation of 1.67. ABR value is precisely based on brokerage recommendations, where out of 15 brokerage recommendations 9 rate Abbott Laboratories (NYSE:ABT) stock a Strong Buy, 2 rate the stocks of the company a Buy, 4 rate Hold, 0 rate Sell and 0 recommend a Strong Sell. Most recently on 6/21/16 the stock of Abbott Laboratories (NYSE:ABT) upgraded by Edward Jones from Hold to Buy. However previously on 1/4/16 it was downgraded by Morgan Stanley from Overweight to Equal-Weight. A research note issued on 11/13/15 the stock was downgraded by Goldman from Buy to Neutral.
Abbott Laboratories (NYSE:ABT) performance over the past one year soared 18.74% whereas its year to date (YTD) performance indicated a bullish trend of 18.86%. During the last six months the stock climbed 8.97%. Quarterly performance of the company shows optimistic momentum of 18.80% while its last one month trend is positive with 6.91%. Stock’s weekly performance expressed down trend of -0.50%.
The company’s price sits 8.10% above from its 50-day moving average of $43.06 and 11.34% far from the stock’s 200-day moving average which is $41.11. Abbott Laboratories (NYSE:ABT)’s shares are currently trading -1.05% away from the 52-week high price of $45.84 and +25.75% far from the 52-week low price of $36.07.
According to consensus agreement of 14 analysts Abbott Laboratories (NYSE:ABT) will report earnings per share of $0.43 in their quarterly report and it is expected to announce the company’s results on 4/19/17. For the current quarter the company has high EPS estimates of $0.43 in contradiction of low EPS estimates of $0.43. However a year ago for the same quarter the company has reported $0.41 EPS. Current year EPS projections for Abbott Laboratories (NYSE:ABT) set at $2.45 according to the sentiments of 17 analysts, while its lowest earnings estimates are $2.43 and highest earnings estimates are $2.48.
According to 13 analysts, Abbott Laboratories (NYSE:ABT)’s revenue estimates for the current quarter are $6.16B meanwhile the company has high revenue estimates of $6.36B in contradiction of low revenue estimates of $6.01B. For the current year the company’s revenue estimates are $26.13B compared to low analyst estimates of $25.88B and high estimates of $26.65B according to the projection of 16 analysts.